MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
-0.070
-5.19%
Pre Market: 1.370 +0.09 +7.03% 08:09 03/08 EST
OPEN
1.370
PREV CLOSE
1.350
HIGH
1.404
LOW
1.170
VOLUME
1.74K
TURNOVER
--
52 WEEK HIGH
3.500
52 WEEK LOW
0.5552
MARKET CAP
35.65M
P/E (TTM)
-1.4145
1D
5D
1M
3M
1Y
5Y
DJ Salarius Pharma Shares Fall After Stock Offering Prices
Dow Jones · 3d ago
Salarius Pharmaceuticals prices $20M stock offering
Salarius Pharmaceuticals (SLRX) trades 12.4% down premarket after pricing its underwritten public offering of 14.6M shares at $1.3685/share.Underwriters granted 45-day option to purchase up to 2.1M shares.Gross proceeds expected to be ~$20M.Offer close exp...
Seekingalpha · 3d ago
BRIEF-Salarius Announces Pricing Of $20 Million Underwritten Public Offering Of Common Stock
reuters.com · 3d ago
Okta, Schrodinger leads the premarket losers' pack
Schrodinger (SDGR) -25% on Q4 earnings release.Purple Innovation (PRPL) -21% on Q4 earning release.Qutoutiao (QTT) -20% on Q4 earning release.Yext (YEXT) -19% on Q4 earning release.Vroom (VRM) -15% on Q4 earning release.KemPharm (KMPH) -13%.Salarius Pharma...
Seekingalpha · 3d ago
BRIEF-Salarius Announces Proposed Public Offering Of Common Stock
reuters.com · 4d ago
Salarius Pharmaceuticals readies stock offering
Salarius Pharmaceuticals (SLRX) trades 5.6% down after hours on commencing an underwritten public offering of shares.Offer size, terms not yet disclosed.
Seekingalpha · 4d ago
Salarius Announces Proposed Public Offering of Common Stock
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has commenced an underwritten public ...
GlobeNewswire · 4d ago
Salarius Commences Underwritten Public Offering; Size, Price to Be Determined
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLRX. Analyze the recent business situations of Salarius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLRX stock price target is 4.433 with a high estimate of 5.00 and a low estimate of 3.800.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 4.27M
% Owned: 15.34%
Shares Outstanding: 27.85M
TypeInstitutionsShares
Increased
5
261.61K
New
9
3.31M
Decreased
3
58.31K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
William McVicar
President/Chief Executive Officer/Director
David Arthur
Chief Financial Officer/Executive Vice President - Finance
Mark Rosenblum
Chief Operating Officer
Kathie Lindemann
Senior Vice President
Nadeem Mirza
Chief Scientific Officer/Director
Bruce McCreedy
Chief Scientific Officer/Director
Bruce Mccreedy
Lead Director/Independent Director
Paul Lammers
Independent Director
Tess Burleson
Independent Director
Arnold Hanish
Independent Director
Jonathan Lieber
No Data
  • All
  • Financials
  • Insiders
More
About SLRX
Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.